Project Details
Description
The aim of this study is to evaluate nedosiran in participants 11 years of age and younger who have Primary Hyperoxaluria with relatively intact renal function.
| Acronym | PHYOX8 |
|---|---|
| Status | Finished |
| Effective start/end date | 22/02/22 → 31/12/24 |
Collaborative partners
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (lead)
- Dubai Health Authority
Keywords
- PH1
- PH2
- PH3
- pediatric
- Hyperoxaluria
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Carbohydrate Metabolism
- Inborn Errors
- Metabolism
- Genetic Diseases
- Inborn
- Metabolic Diseases
- Hyperoxaluria, Primary
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.